Immune approaches in tuberculosis therapy: a brief overview

References

• Erokhin VV, Zemskova ZS. Current views of tuberculosis inflammation. Probl. Tuberk.3, 11–21 (2003).
   Google Scholar
• Dannenberg AM Jr, Collins FM. Progressive pulmonary tuberculosis is not due to increasing numbers of viable bacilli in rabbits, mice and guinea pigs, but is due to a continuous host response to mycobacterial products. Tuberculosis81, 229–242 (2001).
   PubMed Web of Science ®Google Scholar
• Cohen J. Shots in the Dark: The Wayward Search for an AIDS Vaccine. W.W Norton & Company, London, UK (2001).
   Google Scholar
• Kaufmann SH. Introduction. Rational vaccine development against tuberculosis: “Those who don’t remember the past are condemned to repeat it”. Microbes Infect.7, 897–898 (2005).
   PubMed Web of Science ®Google Scholar
• Vilaplana C, Cardona PJ. Tuberculin immunotherapy: its history and lessons to be learned. Microbes Infect.12, 99–105 (2010).
   PubMed Web of Science ®Google Scholar
• Hoft DF, Brown RM, Belshe RB. Mucosal Bacille Calmette-Guérin vaccination of humans inhibits delayed-type hypersensitivity to purified protein derivative but induces mycobacteria-specific interferon-γ responses. Clin. Infect. Dis.30(Suppl. 3), 217–222 (2000).
   PubMed Web of Science ®Google Scholar
• Brandt L, Feino Cunha J, Weinreich Olsen A et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect. Immun.70, 672–678 (2002).
   PubMed Web of Science ®Google Scholar
• Stanford JL, Shield MJ, Rook GA. How environmental mycobacteria may predetermine the protective efficacy of BCG. Tubercle62, 55–62 (1981).
   PubMedGoogle Scholar
• Krylov VA, Gergert VIa, Korotkova ED, Kuz’mina NV, Filippov AV. Tuberculin-BCG therapy in combined treatment of patients with pulmonary tuberculosis. Probl. Tuberk.4, 11–14 (1995).
   Google Scholar
• von Reyn CF, Mtei L, Arbeit RD et al. DarDar study group. Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS24, 675–685 (2010).
   PubMed Web of Science ®Google Scholar
• Burke DS. Of postulates and peccadilloes: Robert Koch and vaccine (tuberculin) therapy for tuberculosis. Vaccine11, 795–804 (1993).
   PubMed Web of Science ®Google Scholar
• Radaeva TV, Nikonenko BV, Kapina MA, Mishchenko VV, Apt AS. Experimental approaches to designing vaccines against tuberculous infection reactivation. Probl. Tuberk.5, 45–48 (2006).
   Google Scholar
• Mirzoian EZ. On the method of tuberculin therapy of pulmonary tuberculosis in adults. Probl. Tuberk.42, 33–38 (1964).
   PubMedGoogle Scholar
• Churchyard GJ, Kaplan G, Fallows D, Wallis RS, Onyebujoh P, Rook GA. Advances in immunotherapy for tuberculosis treatment. Clin. Chest Med.30, 769–782 (2009).
   PubMed Web of Science ®Google Scholar
• Sula L, Radkovský I. Protective effects of M. microti vaccine against tuberculosis. J. Hyg. Epidemiol. Microbiol. Immunol.20, 1–6 (1976).
   PubMedGoogle Scholar
• Zhao GR, Feng DH. A systematic review of inactivated Mycobacterium phlei injection for adjunctive treatment of drug resistant pulmonary tuberculosis. Pharm. J. Chin. PLA25, 361–364 (2009).
   Google Scholar
• Nyasulu PS. Role of adjunctive Mycobacterium w immunotherapy for tuberculosis. J. Exp. Clin. Med.2, 123–129 (2010).
   Google Scholar
• Lei JP, Xiong GL, Hu QF et al. Immunotherapeutic efficacy of BCG vaccine in pulmonary tuberculosis and its preventive effect on multidrug-resistant tuberculosis. Zhonghua Yu Fang Yi Xue Za Zhi42, 86–89 (2008).
   PubMedGoogle Scholar
• Stanford J, Stanford C, Grange J. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Front. Biosci.9, 1701–1719 (2004).
   PubMed Web of Science ®Google Scholar
• Luo Y, Lu S, Guo S. Immunotherapeutic effect of Mycobacterium vaccae on multi-drug resistant pulmonary tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi23, 85–88 (2000).
   PubMedGoogle Scholar
• Dlugovitzky D, Notario R, Martinel-Lamas D et al. Immunotherapy with oral, heat-killed, Mycobacterium vaccae in patients with moderate to advanced pulmonary tuberculosis. Immunotherapy2, 159–169 (2010).
   PubMed Web of Science ®Google Scholar
• Dryer G. Some new principles in bacterial immunity, their experimental foundation, and their application to the treatment of refractory infections, including tuberculosis. Brit. J. Exp. Pathol.46, 146–176 (1923).
   Google Scholar
• Vilaplana C, Montané E, Pinto S et al. Double-blind, randomized, placebo-controlled Phase 1 clinical trial of the therapeutical antituberculous vaccine RUTI. Vaccine28, 1106–1116 (2010).
   PubMed Web of Science ®Google Scholar
• Arjanova OV, Prihoda ND, Yurchenko LV et al. Phase 2 trial of V-5 Immunitor (V5) in patients with chronic hepatitis C co-infected with HIV and Mycobacterium tuberculosis. J. Vaccines Vaccinat.1, 103 (2010).
   Google Scholar
• Arjanova OV, Prihoda ND, Yurchenko LV et al. Adjunct oral immunotherapy in patients with re-treated, multidrug-resistant or HIV-coinfected TB. Immunotherapy3, 181–191 (2011).
   PubMed Web of Science ®Google Scholar
• Butov DA, Pashkov YN, Stepanenko AL et al. Phase 2b randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB. J. Immune Based Ther. Vaccines9, 3 (2011).
   PubMedGoogle Scholar
• Arjanova OV, Butov DA, Prihoda ND et al. One-month immunotherapy trial in treatment-failed TB patients. Open J. Immunol.1, 50–55 (2011).
   Google Scholar
• Xu M, Luo Y-a, Chen B-w et al. The study on preventive effect of M. smegmatis vaccine for people infected with M. tuberculosis. Drug Evaluation2, 1–5 (2006).
   Google Scholar
• Silin DS, Lyubomska OV, Ershov FI, Frolov VM, Kutsyna GA. Synthetic and natural immunomodulators acting as interferon inducers. Curr. Pharm. Des.15, 1238–1247 (2009).
   PubMed Web of Science ®Google Scholar
• Simbirtsev A, Kolobov A, Zabolotnych N et al. Biological activity of peptide SCV-07 (Bestim) against murine tuberculosis. Russ. J. Immunol.8, 11–22 (2003).
   PubMedGoogle Scholar
• Svistunova AS, Pinegin BV, Selitskaia RP et al. The use of immunomodulator likopid in the combined treatment of pulmonary tuberculosis. Probl. Tuberk.3, 21–25 (2002).
   Google Scholar
• Borzenko AS, Antonov YuV, Popkova NL. Use of polyoksidonium in adjunct therapy of patients with pulmonary tuberculosis. Immunologia2, 41–43 (1999).
   Google Scholar
• Knoring BE, El’kin AV, Smirnov MN, Sakharova IYa, Basek TS, Zhuravleva VYu. Immunocorrection of pulmonary tuberculosis with Ronkoleukin. Probl. Tuberk.5, 26–29 (1999).
   Google Scholar
• Mezentseva MV, Stakhanov VA, Zakharova MV et al. Prospects for immunotherapy in adjunct treatment of infiltrating pulmonary tuberculosis. Biopreparaty2, 20–25 (2011).
   Google Scholar
• Zaitzeva SI, Matveeva SL, Gerasimova TG et al. Treatment of cavitary and infiltrating pulmonary tuberculosis with and without the immunomodulator Dzherelo. Clin. Microbiol. Infect.15, 1154–1162 (2009).
   PubMed Web of Science ®Google Scholar
• Arjanova OV, Prihoda ND, Yurchenko LV et al. Enhancement of efficacy of tuberculosis drugs with Immunoxel (Dzherelo) in HIV-infected patients with active pulmonary tuberculosis. Immunotherapy1, 549–556 (2009).
   PubMed Web of Science ®Google Scholar
• Prihoda ND, Arjanova OV, Yurchenko LV et al. Adjuvant immunotherapy of extensively drug-resistant tuberculosis (XDR-TB) in Ukraine. Curr. Res. TB1, 1–6 (2009).
   Google Scholar
• Mezentseva MV, Stakhanov VA, Zakharova MV, Zotova IF, Tregubova MI, Shapoval IM. Cytokines as the markers of the infiltrative pulmonary tuberculosis progress. Infect. Immun.1, 367–372 (2011).
   Google Scholar
• Grange JM, Brunet LR, Rieder HL. Immune protection against tuberculosis – when is immunotherapy preferable to vaccination? Tuberculosis91, 179–185 (2011).
   PubMed Web of Science ®Google Scholar
• Ellner JJ. Immunoregulation in TB; observations and implications. Clin. Transl. Sci.3, 23–28 (2010).
   PubMed Web of Science ®Google Scholar
• Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y. Infections and autoimmunity – friends or foes? Trends Immunol.30, 409–411 (2009).
   PubMed Web of Science ®Google Scholar
• Danelishvili L, McGarvey J, Li YJ, Bermudez LE. Mycobacterium tuberculosis infection causes different levels of apoptosis and necrosis in human macrophages and alveolar epithelial cells. Cell Microbiol.5, 649–660 (2003).
   PubMed Web of Science ®Google Scholar
• Ryan RC, O’Sullivan MP, Keane J. Mycobacterium tuberculosis infection induces non-apoptotic cell death of human dendritic cells. BMC Microbiol.11, 237 (2011).
   PubMedGoogle Scholar
• Gadea I, Zapardiel J, Ruiz P, Gegúndez MI, Esteban J, Soriano F. Cytopathic effect mimicking virus culture due to Mycobacterium tuberculosis. J. Clin. Microbiol.31, 2517–2518 (1993).
   PubMed Web of Science ®Google Scholar
• Lehmann D, Ben-Nun A. Bacterial agents protect against autoimmune disease. I. Mice pre-exposed to Bordetella pertussis or Mycobacterium tuberculosis are highly refractory to induction of experimental autoimmune encephalomyelitis. J. Autoimmun.5, 675–690 (1992).
   PubMed Web of Science ®Google Scholar